Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Human amnion cells for the prevention of bronchopulmonary dysplasia: a protocol for a phase I dose escalation study.

Baker EK, Malhotra A, Lim R, Jacobs SE, Hooper SB, Davis PG, Wallace EM.

BMJ Open. 2019 Mar 1;9(2):e026265. doi: 10.1136/bmjopen-2018-026265.

2.

First-In-Human Administration of Allogeneic Amnion Cells in Premature Infants With Bronchopulmonary Dysplasia: A Safety Study.

Lim R, Malhotra A, Tan J, Chan ST, Lau S, Zhu D, Mockler JC, Wallace EM.

Stem Cells Transl Med. 2018 Sep;7(9):628-635. doi: 10.1002/sctm.18-0079. Epub 2018 Aug 5.

3.

Inhalation or instillation of steroids for the prevention of bronchopulmonary dysplasia.

Bassler D.

Neonatology. 2015;107(4):358-9. doi: 10.1159/000381132. Epub 2015 Jun 5. Review.

PMID:
26044104
4.

Effect of Inhaled Nitric Oxide on Survival Without Bronchopulmonary Dysplasia in Preterm Infants: A Randomized Clinical Trial.

Hasan SU, Potenziano J, Konduri GG, Perez JA, Van Meurs KP, Walker MW, Yoder BA; Newborns Treated With Nitric Oxide (NEWNO) Trial Group.

JAMA Pediatr. 2017 Nov 1;171(11):1081-1089. doi: 10.1001/jamapediatrics.2017.2618.

5.

Human amnion cells reverse acute and chronic pulmonary damage in experimental neonatal lung injury.

Zhu D, Tan J, Maleken AS, Muljadi R, Chan ST, Lau SN, Elgass K, Leaw B, Mockler J, Chambers D, Leeman KT, Kim CF, Wallace EM, Lim R.

Stem Cell Res Ther. 2017 Nov 10;8(1):257. doi: 10.1186/s13287-017-0689-9.

6.

Systemic corticosteroid regimens for prevention of bronchopulmonary dysplasia in preterm infants.

Onland W, De Jaegere AP, Offringa M, van Kaam A.

Cochrane Database Syst Rev. 2017 Jan 31;1:CD010941. doi: 10.1002/14651858.CD010941.pub2. Review.

7.

The N3RO trial: a randomised controlled trial of docosahexaenoic acid to reduce bronchopulmonary dysplasia in preterm infants < 29 weeks' gestation.

Collins CT, Gibson RA, Makrides M, McPhee AJ, Sullivan TR, Davis PG, Thio M, Simmer K, Rajadurai VS; N3RO Investigative Team.

BMC Pediatr. 2016 Jun 1;16:72. doi: 10.1186/s12887-016-0611-0.

8.

Enteral vitamin A for reducing severity of bronchopulmonary dysplasia in extremely preterm infants: a randomised controlled trial.

Rakshasbhuvankar A, Patole S, Simmer K, Pillow JJ.

BMC Pediatr. 2017 Dec 16;17(1):204. doi: 10.1186/s12887-017-0958-x.

9.

Inhaled versus systemic corticosteroids for preventing bronchopulmonary dysplasia in ventilated very low birth weight preterm neonates.

Shah SS, Ohlsson A, Halliday HL, Shah VS.

Cochrane Database Syst Rev. 2017 Oct 17;10:CD002058. doi: 10.1002/14651858.CD002058.pub3. Review.

10.

Inositol in preterm infants at risk for or having respiratory distress syndrome.

Howlett A, Ohlsson A, Plakkal N.

Cochrane Database Syst Rev. 2019 Jul 8;7:CD000366. doi: 10.1002/14651858.CD000366.pub4.

PMID:
31283839
11.

Two-year outcomes of infants enrolled in the first-in-human study of amnion cells for bronchopulmonary dysplasia.

Malhotra A, Lim R, Mockler JC, Wallace EM.

Stem Cells Transl Med. 2019 Nov 27. doi: 10.1002/sctm.19-0251. [Epub ahead of print]

12.

Early (< 8 days) systemic postnatal corticosteroids for prevention of bronchopulmonary dysplasia in preterm infants.

Doyle LW, Cheong JL, Ehrenkranz RA, Halliday HL.

Cochrane Database Syst Rev. 2017 Oct 24;10:CD001146. doi: 10.1002/14651858.CD001146.pub5. Review.

13.

Effect of Hydrocortisone Therapy Initiated 7 to 14 Days After Birth on Mortality or Bronchopulmonary Dysplasia Among Very Preterm Infants Receiving Mechanical Ventilation: A Randomized Clinical Trial.

Onland W, Cools F, Kroon A, Rademaker K, Merkus MP, Dijk PH, van Straaten HL, Te Pas AB, Mohns T, Bruneel E, van Heijst AF, Kramer BW, Debeer A, Zonnenberg I, Marechal Y, Blom H, Plaskie K, Offringa M, van Kaam AH; STOP-BPD Study Group.

JAMA. 2019 Jan 29;321(4):354-363. doi: 10.1001/jama.2018.21443.

14.

Validation of the National Institutes of Health consensus definition of bronchopulmonary dysplasia.

Ehrenkranz RA, Walsh MC, Vohr BR, Jobe AH, Wright LL, Fanaroff AA, Wrage LA, Poole K; National Institutes of Child Health and Human Development Neonatal Research Network.

Pediatrics. 2005 Dec;116(6):1353-60.

PMID:
16322158
15.

Inhaled versus systemic corticosteroids for the treatment of bronchopulmonary dysplasia in ventilated very low birth weight preterm infants.

Shah SS, Ohlsson A, Halliday HL, Shah VS.

Cochrane Database Syst Rev. 2017 Oct 16;10:CD002057. doi: 10.1002/14651858.CD002057.pub4. Review.

16.

[The use of postnatal corticosteroid therapy in premature infants to prevent or treat bronchopulmonary dysplasia: current situation and recommendations].

Jarreau PH, Fayon M, Baud O, Autret-Leca E, Danan M, de Verdelhan A, Castot A.

Arch Pediatr. 2010 Oct;17(10):1480-7. doi: 10.1016/j.arcped.2010.07.013. Epub 2010 Sep 22. French.

PMID:
20864322
17.

Delivery room interventions to prevent bronchopulmonary dysplasia in preterm infants: a protocol for a systematic review and network meta-analysis.

Mitra S, Disher T, Pichler G, D'Souza B, Mccord H, Chayapathi V, Jones K, Schmölzer G.

BMJ Open. 2019 Aug 18;9(8):e028066. doi: 10.1136/bmjopen-2018-028066.

18.

Late (≥ 7 days) inhalation corticosteroids to reduce bronchopulmonary dysplasia in preterm infants.

Onland W, Offringa M, van Kaam A.

Cochrane Database Syst Rev. 2017 Aug 24;8:CD002311. doi: 10.1002/14651858.CD002311.pub4. Review.

19.

Systemic Hydrocortisone To Prevent Bronchopulmonary Dysplasia in preterm infants (the SToP-BPD study): statistical analysis plan.

Onland W, Merkus MP, Nuytemans DH, Jansen-van der Weide MC, Holman R, van Kaam AH; SToP-BPD study group.

Trials. 2018 Mar 9;19(1):178. doi: 10.1186/s13063-018-2505-y.

20.

Late (> 7 days) systemic postnatal corticosteroids for prevention of bronchopulmonary dysplasia in preterm infants.

Doyle LW, Cheong JL, Ehrenkranz RA, Halliday HL.

Cochrane Database Syst Rev. 2017 Oct 24;10:CD001145. doi: 10.1002/14651858.CD001145.pub4. Review.

Supplemental Content

Support Center